CVRx Reports Third Quarter 2026 Financial and Operating Results
Key Highlights
- ➤Q3 revenue $13.8 million, down 6% year over year
- ➤2026 revenue guidance cut to $56.0-$57.0 million from $58.0-$60.0 million
- ➤Q3 net loss widened to $14.2 million, or $0.52 per share
- ➤Second major Medicare Advantage policy brings coverage to approximately 21% of enrollment
- ➤U.S. active implanting centers rose to 262 from 250 year over year
Expert Statements
Kevin Hykes, President and Chief Executive Officer of CVRx
“While we recognize there is more work ahead, we remain encouraged by the progress we are making on key strategic initiatives, including the expansion of Medicare Advantage coverage and the clinical evidence released at HFSA”
Kevin Hykes, President and Chief Executive Officer of CVRx
“With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with heart failure.”
Dmitry Yaranov, M.D. of Baptist Memorial Health Care
“Improvements in New York Heart Association (NYHA) functional class and an increase in average left ventricular ejection fraction (LVEF) were observed over follow-up, while blood pressure and other hemodynamic parameters remained stable.”
MINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2026.
Recent Highlights * Total revenue for the third quarter of 2026 was $13.8 million * U.S. revenue for the third quarter of 2026 was $13.0 million * Active implanting centers in the U.S. increased to 262 as of September 30, 2026, as compared to 250 as of September 30, 2025 * A second major Medicare Advantage provider has issued a coverage policy for Barostim, effective July 17, 2026, covering the current FDA-approved indication and patients enrolled in BENEFIT-HF. In total, these two policies represent approximately 21% of Medicare Advantage enrollment * Had a significant presence at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 including podium presentations featuring late-breaking REBALANCE Registry data as well as new real-world evidence in patients with heart failure with mildly reduced ejection fraction (HFmrEF) * Appointed John Landry as Chief Financial Officer effective November 6, 2026, bringing more than 20 years of financial leadership experience in the medical device industry “While we recognize there is more work ahead, we remain encouraged by the progress we are making on key strategic initiatives, including the expansion of Medicare Advantage coverage and the clinical evidence released at HFSA,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with heart failure.”
Get started
Create a free account to read the full story.